Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Erlotinib Tablets (US RLD: Tarceva Tablets), in the strengths of 25 mg, 100 mg, and 150 mg.
Erlotinib is a cancer medicine that interferes with the growth of cancer cells and slows their spread in the body. It is also used to treat non-small cell lung cancer or pancreatic cancer that has spread to other parts of the body (metastatic). Erlotinib is usually given after other cancer medicines have been tried without success. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, in Ahmedabad.
The group now has 288 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: